Fetal serotonin signaling: setting pathways for early childhood development and behavior

J Adolesc Health. 2012 Aug;51(2 Suppl):S9-16. doi: 10.1016/j.jadohealth.2012.04.009.

Abstract

Finely tuning levels of the key neurotransmitter serotonin (5-hydroxytryptamine [5-HT]) during early life is essential for brain development and setting pathways for health and disorder across the early life span. Given the central role of 5-HT in brain development, regulation of mood, stress reactivity, and risk for psychiatric disorders, alterations in 5-HT signaling early in life have critical implications for behavior and mental health in childhood and adolescence. This article reviews the developmental consequences of two key influences that alter fetal 5-HT signaling: (1) in utero exposure to 5-HT reuptake inhibitor antidepressants, and (2) genetic variations in the 5-HT transporter gene (SLC6A4). The consequences of altered prenatal 5-HT signaling vary greatly, and developmental outcomes depend on an ongoing interplay between biological (genetic/epigenetic variations), experiential (prenatal drug or maternal mood exposure), and contextual (postnatal social environment) variables. Emerging evidence suggests both exposure to 5-HT reuptake inhibitors and genetic variations that affect 5-HT signaling may increase sensitivity to negative social contexts for some individuals, whereas for others, they may confer sensitivity to positive life circumstances. In this sense, factors that change central 5-HT levels may function less like influences that predict "vulnerability," but rather act like "plasticity factors." Understanding the impact of early changes in serotonergic programming offers critical insights that might explain patterns of individual differences in developmental risk and resilience.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Adolescent
  • Adolescent Behavior / drug effects
  • Antidepressive Agents, Second-Generation / adverse effects
  • Antidepressive Agents, Second-Generation / therapeutic use
  • Brain / drug effects
  • Brain / embryology*
  • Brain / metabolism
  • Child
  • Child Behavior / drug effects*
  • Child Behavior / physiology
  • Child Development / drug effects*
  • Child Development / physiology
  • Depressive Disorder / drug therapy
  • Female
  • Human Development / drug effects
  • Human Development / physiology
  • Humans
  • Maternal Exposure / adverse effects
  • Pregnancy
  • Pregnancy Complications / drug therapy*
  • Pregnancy Complications / metabolism
  • Prenatal Exposure Delayed Effects / genetics*
  • Risk Factors
  • Selective Serotonin Reuptake Inhibitors / adverse effects*
  • Selective Serotonin Reuptake Inhibitors / therapeutic use
  • Serotonin Plasma Membrane Transport Proteins / genetics*
  • Serotonin Plasma Membrane Transport Proteins / metabolism

Substances

  • Antidepressive Agents, Second-Generation
  • SLC6A4 protein, human
  • Serotonin Plasma Membrane Transport Proteins
  • Serotonin Uptake Inhibitors